Estudios

Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023; 61: 2202071 Interpretation Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must take into consideration the risk of viral infection

Presenta Dr. Felipe Cayupi

06 de septiembre 2023 16:00hrs / 17:15hrs

Association Between Nocturnal Hypoxemia and Cancer Incidence in Patients Investigated for OSA Data From a Large Multicenter French Cohort. CHEST 2020; 158(6):2610-2620. I NTERPRETATION: Nocturnal hypoxemia was associated with all-cancer incidence in patients investigated for OSA. Whether OSA therapy might reduce the risk of cancer needs further evaluation

Presenta Dra. María Belén Fernández

23 de agosto 2023 16:00hrs / 17:15hrs

Patrick W. Sullivan. Association Between Pulmonary Function and Asthma Symptoms. J ALLERGY CLIN IMMUNOL PRACT SEPTEMBER/OCTOBER 2019

Presenta Dr. Max Kauffmann

16 de agosto 2023 16:00hrs / 17:15hrs

Andrei M Darie. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med 2022;10: 877–87 Interpretation Multiplex bacterial PCR examination of bronchoalveolar lavage decreases the duration of inappropriate antibiotic therapy of patients admitted to hospital with pneumonia and at risk of Gram-negative rod infection. This approach warrants further consideration in future antibiotic stewardship strategies.

Presenta Dr. Javier Riquelme

09 de agosto 2023 16:00hrs / 17:15hrs

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 2023;389:205-14. Among patients with COPD who had type 2 inflammation as indicated by elevated blood eosinophil counts, those who received dupilumab had fewer exacerbations, better lung function and quality of life, and less severe respiratory symptoms than those who received placebo.

Presenta Dr. Patricio Pérez

02 de agosto 2023 16:00hrs / 17:15hrs